Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;31(12):1786-1795.
doi: 10.1038/s41417-024-00842-z. Epub 2024 Oct 8.

AMIGO2 enhances the invasive potential of colorectal cancer by inducing EMT

Affiliations

AMIGO2 enhances the invasive potential of colorectal cancer by inducing EMT

Runa Izutsu et al. Cancer Gene Ther. 2024 Dec.

Abstract

In our previous studies, we identified amphoterin-inducible gene and open reading frame 2 (AMIGO2) as a driver gene for liver metastasis and found that AMIGO2 expression in cancer cells worsens the prognosis of patients with colorectal cancer (CRC). Epithelial-mesenchymal transition (EMT) is a trigger for CRC to acquire a malignant phenotype, such as invasive potential, leading to metastasis. However, the role of AMIGO2 expression in the invasive potential of CRC cells remains unclear. Thus, this study aimed to examine AMIGO2 expression and elucidate the mechanisms by which it induces EMT and promotes CRC invasion. Activation of the TGFβ/Smad signaling pathway was found involved in AMIGO2-induced EMT, and treatment with the TGFβ receptor inhibitor LY2109761 suppressed AMIGO2-induced EMT. Studies using CRC samples showed that AMIGO2 expression was highly upregulated in the invasive front, where AMIGO2 expression was localized to the nucleus and associated with EMT marker expression. These results suggest that the nuclear translocation of AMIGO2 induces EMT to promote CRC invasion by activating the TGFβ/Smad signaling pathway. Thus, AMIGO2 is an attractive therapeutic target for inhibiting EMT and metastatic CRC progression.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate: The study followed the Declaration of Helsinki principles and was approved by the Institutional Review Board of the Faculty of Medicine at Tottori University (approval number: 17A142). The informed consent was obtained from all subjects. Competing interests: The authors declare no competing interests.

References

    1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233–54. - DOI - PubMed
    1. Rumpold H, Niedersüß-Beke D, Heiler C, Falch D, Wundsam HV, Metz-Gercek S, et al. Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. BMC Cancer. 2020;20:1149. - DOI - PubMed - PMC
    1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93. - DOI - PubMed
    1. Kanda Y, Osaki M, Onuma K, Sonoda A, Kobayashi M, Hamada J, et al. Amigo2-upregulation in tumour cells facilitates their attachment to liver endothelial cells resulting in liver metastases. Sci Rep. 2017;7:43567. - DOI - PubMed - PMC
    1. Izutsu R, Osaki M, Jehung JP, Seong HK, Okada F. Liver metastasis formation is defined by AMIGO2 expression via adhesion to hepatic endothelial cells in human gastric and colorectal cancer cells. Pathol Res Pract. 2022;237:154015. - DOI - PubMed

LinkOut - more resources